Learn

This is a summary of the Australian & New Zealand Urogenital and Prostate Cancer Trials Group 2026 Conference Review which was held in Adelaide 28 - 30 June.

Commentary provided by Dr Umbreen Hafeez.

Details

In this edition we feature:

-  Exploratory spatial biomarkers in primary prostate cancer
-  Reducing BCG toxicity via sensory pathways
-  Aspartate metabolism in castration/enzalutamide-resistant prostate cancer
-  ctDNA testing in metastatic prostate cancer
-  Complex treatment decision-making in genitourinary oncology
-  The growing financial burden of cancer care
-  Lu-PSMA, the TME & prostate cancer cell differentiation
-  The Plasmalogen Score in metastatic prostate cancer
-  Drivers of progression in aggressive prostate cancer
-  PSMA-PET in low- to favourable-intermediate-risk prostate cancer
-  Cxbladder Triage Plus for suspected urothelial carcinoma

To access this publication please click ‘Enrol Now’ and you’ll be directed to  the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au

This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide. 

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.